Skip to main content

MINI REVIEW article

Front. Endocrinol.
Sec. Clinical Diabetes
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1520313
This article is part of the Research Topic Disease-modifying approaches in type 1 diabetes View all 11 articles

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) and Type 1 Diabetes: A Potential Game Changer?

Provisionally accepted
  • 1 University of Alabama at Birmingham, Birmingham, United States
  • 2 Comprehensive Diabetes Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States

The final, formatted version of the article will be published soon.

    This mini review explores the increasing prevalence of obesity in type 1 diabetes (T1D) and the challenges patients face in achieving optimal glycemic control with current treatments. It discusses the evidence supporting the use of glucagon-like peptide-1 receptor agonists (GLP-1RA) as potential adjunctive therapy in T1D to reduce weight and improve insulin resistance. Potential benefits need to be weighed against the risk of hypoglycemia and lack of long-term data.

    Keywords: CSII-continuous subcutaneous insulin infusion, GLP-1-glucagon-like peptide-1, GLP-1RA-glucagon-like peptide-1 receptor agonists, IR-insulin resistance, MDI-multiple daily injections, RCT-randomized controlled trial, T1D-type 1 diabetes, T2D-type 2 diabetes

    Received: 31 Oct 2024; Accepted: 26 Dec 2024.

    Copyright: © 2024 Resnick, Bril and Beauchamp. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Giovanna Beauchamp, University of Alabama at Birmingham, Birmingham, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.